CFO Gall Matthew buys 5,000 ITOS shares at $7.73 amid -54.9% 90-day decline; stock down -56.3% from 52-week high.
CFO Matthew Gall purchased 5,000 shares of iTeos Therapeutics at $7.73, raising his holdings from 60,429 to 65,429 shares, in a context of severe recent price deterioration: the stock has declined 54.9% over 90 days and is -56.3% below its 52-week high of $18.09. The company is unprofitable with net income of $-45,358,000 and quarterly revenue of $0.00, alongside a -95.3% decline in annual revenue growth. Gall's cross-ticker insider buy track record shows 1 prior purchase with a 100.00% 90-day win rate and +29.8% average 90d return; at ITOS specifically, his single prior buy on 2023-10-12 did produce a +29.8% 90-day return and was well-timed. This buy occurs in a substantially depressed price environment relative to both recent history and the insider's own demonstrated timing patterns elsewhere, yet the company's operational deterioration and cash burn constraints warrant scrutiny of its trajectory.